SEC Info - Ziopharm Oncology Inc - ‘10-K’ for 12/31/09

SEC Info℠

Home

Help

Please Sign In

Ziopharm Oncology Inc – ‘10-K’ for 12/31/09 – ‘EX-33.2’

On: Wednesday, 3/17/10, at 5:11pm ET · For: 12/31/09 · Accession #: 1144204-10-14169 · File #: 1-33038

  As Of                Filer                Filing    For·On·As Docs:Size              Issuer               Agent

 3/17/10  Ziopharm Oncology Inc             10-K       12/31/09    7:1.3M                                   Toppan Vintage/FA

Annual Report — Form 10-K
Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML    607K 
 2: EX-10.16    Material Contract                                   HTML     16K 
 3: EX-23.1     Consent of Experts or Counsel                       HTML      9K 
 7: EX-33.2     ABS - Report of Compliance with Servicing Criteria  HTML     10K 
 4: EX-31.1     Certification -- Sarbanes-Oxley Act - Sect. 302     HTML     16K 
 5: EX-31.2     Certification -- Sarbanes-Oxley Act - Sect. 302     HTML     16K 
 6: EX-32.1     Certification -- Sarbanes-Oxley Act - Sect. 906     HTML     10K

EX-33.2 — ABS – Report of Compliance with Servicing Criteria

This Exhibit is an HTML Document rendered as filed. [ Alternative Formats ]

Unassociated Document

C: C: C:

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Annual Report of ZIOPHARM Oncology, Inc. (the “Company”) on Form 10-K for the year ended December 31, 2009, as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Richard Bagley, Principal Financial Officer of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

	(1)	The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

	(2)	The information contained in the Report fairly presents, in all material respects, the financial condition and result of operations of the Company.

/s/ Richard E. Bagley

Richard E. Bagley, President and

Chief Financial Officer

(Principal Financial and Accounting Officer)

March 17, 2010

Dates Referenced Herein and Documents Incorporated by Reference

This ‘10-K’ Filing	Date	Other Filings

Filed on:	3/17/10	8-K
For Period End:	12/31/09	10-K/A, 4
		List all Filings

3 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

12/21/10  SEC                               UPLOAD¶     9/23/17    1:47K  Alaunos Therapeutics, Inc.
12/03/10  SEC                               UPLOAD¶     9/23/17    1:54K  Alaunos Therapeutics, Inc.
 9/20/10  SEC                               UPLOAD¶     9/23/17    1:65K  Alaunos Therapeutics, Inc.

↑Top

Filing Submission 0001144204-10-014169 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)